Expertise in
9
conditions

Dr. Tessa Kerre

Hematology | Oncology
Rachel Loschiavo PA-C
825 Eastlake Ave E, 
Seattle, WA 
Expertise in
9
conditions
Rachel Loschiavo PA-C
825 Eastlake Ave E, 
Seattle, WA 

Overview

Tessa Kerre is a Hematologist and an Oncologist practicing medicine in Seattle, Washington.

Dr. Kerre is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Common Variable Immune Deficiency, Secondary Immunodeficiency (SID), and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 104 peer reviewed articles and participating in 8 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in WA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Rachel Loschiavo Pa-C
825 Eastlake Ave E, Seattle, WA 98109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Enrollment Status: Terminated
Publish Date: October 20, 2025
Intervention Type: Drug
Study Drugs: Itacitinib, Methylprednisolone, Prednisone
Study Phase: Phase 2/Phase 3
Bibliotherapy, Students in Medicine and Health Sciences Read to Patients With Cancer During Treatment, an Evaluation by Patients and Students.
Bibliotherapy, Students in Medicine and Health Sciences Read to Patients With Cancer During Treatment, an Evaluation by Patients and Students.
Enrollment Status: Completed
Publish Date: April 17, 2024
Intervention Type: Behavioral
Study Phase: Not Applicable
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug, Other
Study Phase: Phase 3
CMV Specific T Cell Therapy for the Treatment of Relapsing or Therapy Refractory CMV Infection After Allogeneic Stem Cell Transplantation With a CMV-positive Donor.
CMV Specific T Cell Therapy for the Treatment of Relapsing or Therapy Refractory CMV Infection After Allogeneic Stem Cell Transplantation With a CMV-positive Donor.
Enrollment Status: Completed
Publish Date: December 21, 2022
Intervention Type: Genetic, Drug
Study Drug: Standard Anti-Viral Therapy
Study Phase: Phase 2
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant
Enrollment Status: Completed
Publish Date: March 02, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
Co-transplantation of Mesenchymal Stem Cells and HLA-mismatched Allogeneic Hematopoietic Cells After Nonmyeloablative Conditioning: a Phase II Randomized Double-blind Study
Co-transplantation of Mesenchymal Stem Cells and HLA-mismatched Allogeneic Hematopoietic Cells After Nonmyeloablative Conditioning: a Phase II Randomized Double-blind Study
Enrollment Status: Terminated
Publish Date: September 08, 2021
Intervention Type: Other, Biological
Study Drug: Mesenchymal Stem Cells
Study Phase: Phase 2
TK008: Randomized Phase III Trial of Haploidentical HCT With or Without an Add Back Strategy of HSV-Tk Donor Lymphocytes in Patients With High Risk Acute Leukemia
TK008: Randomized Phase III Trial of Haploidentical HCT With or Without an Add Back Strategy of HSV-Tk Donor Lymphocytes in Patients With High Risk Acute Leukemia
Enrollment Status: Terminated
Publish Date: June 22, 2021
Intervention Type: Genetic, Other
Study Phase: Phase 3
An Open-label, Phase I/II Study to Assess the Safety and Clinical Activity of NKR-2 Treatment Administration After a Non-myeloablative Preconditioning Chemotherapy in Relapse/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients.
An Open-label, Phase I/II Study to Assess the Safety and Clinical Activity of NKR-2 Treatment Administration After a Non-myeloablative Preconditioning Chemotherapy in Relapse/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients.
Enrollment Status: Completed
Publish Date: May 04, 2021
Intervention Type: Biological
Study Drugs: NKR-2 NKG2D-Positive Modified Natural Killer T Cells, Cyclophosphamide, Fludarabine
Study Phase: Phase 1/Phase 2
View 7 Less Clinical Trials

104 Total Publications

Patient-centric capillary dried blood spot sampling for tacrolimus and creatinine monitoring in clinical practice.
Patient-centric capillary dried blood spot sampling for tacrolimus and creatinine monitoring in clinical practice.
Journal: Clinical chemistry and laboratory medicine
Published: March 02, 2026
Similar Doctors
Expertise in
15
conditions
Dr. Douglas Hawkins
Hematology | Oncology
Expertise in
15
conditions
Dr. Douglas Hawkins
Hematology | Oncology
Referral may be required

Seattle Children's Hospital

4800 Sand Point Way NE, 
Seattle, WA 
 (3.3 miles away)
206-987-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Douglas Hawkins is a Hematologist and an Oncologist practicing medicine in Seattle, Washington. Dr. Hawkins is highly rated in 15 conditions, according to our data. His clinical expertise encompasses Rhabdomyosarcoma, Adult Soft Tissue Sarcoma, Osteosarcoma, Osteotomy, and Bone Marrow Aspiration.

Expertise in
17
conditions
Dr. Hans-peter Kiem
Hematology | Oncology
Expertise in
17
conditions
Dr. Hans-peter Kiem
Hematology | Oncology
Referral may be required

Gme Office University Of Washington

1959 NE Pacific St, 
Seattle, WA 
 (1.9 miles away)
206-543-3360
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hans-peter Kiem is a Hematologist and an Oncologist practicing medicine in Seattle, Washington. Dr. Kiem is highly rated in 17 conditions, according to our data. His clinical expertise encompasses X-Linked Severe Combined Immunodeficiency, Severe Combined Immunodeficiency (SCID), Congenital Aplastic Anemia, Fanconi Anemia, and Bone Marrow Transplant.

Expertise in
7
conditions
Dr. Mignon Loh
Hematology | Oncology
Expertise in
7
conditions
Dr. Mignon Loh
Hematology | Oncology
Referral may be required

Seattle Children's Hospital

4800 Sand Point Way NE, 
Seattle, WA 
 (3.3 miles away)
206-987-2106
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mignon Loh is a Hematologist and an Oncologist practicing medicine in Seattle, Washington. Dr. Loh is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Juvenile Myelomonocytic Leukemia (JMML), Splenectomy, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Tessa Kerre

How do I make an appointment with Dr. Tessa Kerre?

You can book an appointment with Dr. Tessa Kerre by calling their office at 206-288-6956. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Tessa Kerre a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Tessa Kerre is classified as an Advanced expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Tessa Kerre specialize in?

While Dr. Tessa Kerre is a Hematology, they have specific expertise in Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Leukemia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Tessa Kerre participate in research or clinical trials?

Yes. Dr. Tessa Kerre has published 104 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Tessa Kerre's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kerre's expertise for a condition
ConditionClose
      View All 9 Advanced Conditions
      View All 12 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile